19 April 2018 - Roche/Chugai’s RoActemra should be routinely offered throughout the NHS to adults with giant cell arteritis within the next three months, following a final green light from cost regulators.

NICE is recommending funding for one year’s treatment with the drug for patients who suffer flares of their giant cell arteritis or may not respond fully to steroids, as their disease is most difficult to control.

Read Pharma Times article